EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Investigating the Use of Melatonin in Children With Atopic Dermatitis: A Cross‐Sectional Study

Sarah Lee, Eun Jae Kim, Jennifer LeBovidge, Itohan Aigbekaen, Laura Berbert, Lynda Schneider, Tina Ho

Pediatric Dermatology · 2025-11 · 42 (6) · 1156-1162

DOI: 10.1111/pde.70041 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background/Objectives Children with atopic dermatitis (AD) frequently experience sleep disturbances. Melatonin, an over‐the‐counter supplement, is increasingly used in the general pediatric population; however, its prevalence and perceived effectiveness in children with AD remain unclear. Methods Caregivers of pediatric patients (ages 1–17 years) with physician‐diagnosed AD completed surveys on melatonin use, Patient Oriented Eczema Measure (POEM), and age‐appropriate sleep questionnaires. Results Among 102 total respondents, 27.5% reported a history of melatonin use, with 10.8% using it in the past 30 days. Gummies were the most common formulation (85.7%), though brands and dosages varied widely (0.5–10 mg; median: 3 mg). 32.1% of caregivers initiated melatonin based on a healthcare professional's recommendations, while the majority initiated use independently (50.0%) or based on recommendations from friends/family (21.4%) or online resources (7.1%). Melatonin use was significantly more common among children with behavioral or psychological comorbidities compared to those without (56.3% vs. 22.1%; p = 0.012). Children ages 6‐17 who used melatonin had significantly higher PROMIS Sleep Disturbance scores than nonusers ( p < 0.001). Perceived effectiveness varied: for sleep, 21.4% of caregivers found melatonin very useful, 32.1% somewhat useful, and 39.3% of little or no use. For nocturnal itch, 14.3% found melatonin very useful, 17.9% somewhat useful, and 50.0% of little or no use. Conclusions There is a high prevalence of melatonin use among children with AD. Most caregivers are initiating melatonin independently, and dosage varies widely. Given mixed caregiver‐reported effectiveness of melatonin and limited long‐term safety data, it is imperative that further studies are performed to evaluate melatonin's role in children with AD.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →